Employees: 02 (2023.0)Legal category: Société à responsabilité limitée (sans autre indication)Size: PMECreation date: 2011-04-07 (15 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: PARIS (75007), Paris
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
PHARMACIE RAMAJO ANCOURT : revenue, balance sheet and financial ratios
PHARMACIE RAMAJO ANCOURT is a French company
founded 15 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in PARIS (75007),
this company of category PME
shows in 2023 a revenue of 1.6 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - PHARMACIE RAMAJO ANCOURT (SIREN 531867067)
Indicator
2025
2023
2022
2019
2018
2017
2016
Revenue
N/C
1 608 180 €
N/C
N/C
N/C
N/C
N/C
Net income
57 554 €
110 369 €
259 965 €
83 009 €
114 100 €
139 612 €
-68 852 €
EBITDA
N/C
158 312 €
N/C
N/C
N/C
N/C
N/C
Net margin
N/C
6.9%
N/C
N/C
N/C
N/C
N/C
Revenue and income statement
In 2025, PHARMACIE RAMAJO ANCOURT generates positive net income of 58 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
57 554 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 28%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 68%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
28.471%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
68.414%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2022
2023
2025
Debt ratio
645.299
352.825
241.842
186.252
80.994
57.489
28.471
Financial autonomy
12.04
19.427
25.464
30.501
47.669
56.258
68.414
Repayment capacity
None
None
None
None
None
5.553
None
Cash flow / Revenue
None%
None%
None%
None%
None%
7.064%
None%
Sector positioning
Debt ratio
28.472025
2022
2023
2025
Q1: 13.7
Med: 49.79
Q3: 129.09
Good-16 pts over 3 years
In 2025, the debt ratio of PHARMACIE RAMAJO ANCOURT (28.47) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
Financial autonomy
68.41%2025
2022
2023
2025
Q1: 33.42%
Med: 53.72%
Q3: 72.08%
Good+19 pts over 3 years
In 2025, the financial autonomy of PHARMACIE RAMAJO ANCOURT (68.4%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
Repayment capacity
5.55 years2023
2023
Q1: 0.95 years
Med: 3.59 years
Q3: 7.48 years
Average
In 2023, the repayment capacity of PHARMACIE RAMAJO ANCOURT (5.55) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 138.78. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2016
2017
2018
2019
2022
2023
2025
Liquidity ratio
99.143
154.836
151.608
148.949
216.489
221.466
138.78
Interest coverage
None
None
None
None
None
5.708
None
Sector positioning
Liquidity ratio
138.782025
2022
2023
2025
Q1: 131.03
Med: 182.25
Q3: 258.64
Average-27 pts over 3 years
In 2025, the liquidity ratio of PHARMACIE RAMAJO ANCOURT (138.78) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
Interest coverage
5.71x2023
2023
Q1: 0.38x
Med: 2.71x
Q3: 6.47x
Good
In 2023, the interest coverage of PHARMACIE RAMAJO ANCOURT (5.7x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2025)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2025)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2025)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2025)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution PHARMACIE RAMAJO ANCOURT
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2022
2023
2025
Operating WCR
0 €
0 €
0 €
0 €
0 €
239 908 €
0 €
Inventory turnover (days)
0
0
0
0
0
42
0
Customer payment term (days)
35
20
32
44
63
6
0
Supplier payment term (days)
609
717
784
818
615
52
0
Positioning of PHARMACIE RAMAJO ANCOURT in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of PHARMACIE RAMAJO ANCOURT is estimated at
914 252 €
(range 620 415€ - 1 434 587€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
620k€914k€1434k€
914 252 €Range: 620 415€ - 1 434 587€
NAF 5 année 2025
Valuation method used
Net Income Multiple
57 554 €
×
15.9x
=914 252 €
Range: 620 416€ - 1 434 587€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare PHARMACIE RAMAJO ANCOURT with other companies in the same sector:
Frequently asked questions about PHARMACIE RAMAJO ANCOURT
What is the revenue of PHARMACIE RAMAJO ANCOURT ?
The revenue of PHARMACIE RAMAJO ANCOURT in 2023 is 1.6 M€.
Is PHARMACIE RAMAJO ANCOURT profitable?
Yes, PHARMACIE RAMAJO ANCOURT generated a net profit of 58 k€ in 2025.
Where is the headquarters of PHARMACIE RAMAJO ANCOURT ?
The headquarters of PHARMACIE RAMAJO ANCOURT is located in PARIS (75007), in the department Paris.
Where to find the tax return of PHARMACIE RAMAJO ANCOURT ?
The tax return of PHARMACIE RAMAJO ANCOURT is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does PHARMACIE RAMAJO ANCOURT operate?
PHARMACIE RAMAJO ANCOURT operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart